Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 196

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 196
---
i) any direct or indirect acquisition, sale, disposition (or any lease or other
arrangement having the same economic effect as a sale or disposition), in a single transaction or a series of related transactions, of assets representing 20% or more of the consolidated assets or contributing 20% or more of the consolidated revenue
of the Company and its Subsidiaries or of 20% or more of the voting, equity or other securities of the Company or any of its Subsidiaries (or rights or interests therein or thereto); (ii) any direct or indirect take-over bid, tender offer, exchange
offer, treasury issuance or other transaction that, if consummated, would result in a Person or group of Persons beneficially owning 20% or more of any class of voting, equity or other securities or any other equity interests (including securities
convertible into or exercisable or exchangeable for securities or equity interests) of the Company or any of its Subsidiaries; (iii) any plan of arrangement, merger, amalgamation, consolidation, share exchange, business combination,
reorganization, recapitalization, joint venture, partnership, liquidation, dissolution, winding up or exclusive license involving the Company or any of its Subsidiaries; (iv) any other similar transaction or series of transactions involving the
Company or any of its Subsidiaries; or (v) any other transaction, the consummation of which would reasonably be expected to impede, prevent or delay the transactions contemplated by the Agreement or the Arrangement.

“Affiliate” has the meaning ascribed thereto in National Instrument
45-106 —Prospectus Exemptions.

“Agreement” means the
Arrangement Agreement dated November 14, 2025, between the Company and the Purchaser, including the schedules attached thereto, as amended, supplemented or otherwise modified from time to time in accordance with the terms thereof.

“allowable capital loss” has the meaning ascribed thereto in “Certain Canadian Federal Income Tax Considerations of the Arrangement” and “Certain Canadian Federal Income Tax Considerations of the Liquidation” as applicable.

“Annual Financial Statements” means the audited consolidated financial statements of the Company as at and for the fiscal
year ended December 31, 2024, together with the notes thereto and the auditor’s report thereon.

“Arrangement” means the arrangement under Chapter XVI – Division II of the QBCA on the terms and subject to the